Confirming “Idiopathic” Before Committing Him to Verapamil
A single patient whose ECG pattern is classic for a benign, treatable diagnosis, with one imaging study left to complete before the standard drug for that diagnosis is started for the long term.
S.B., a 27-year-old man, operates a forklift at a regional distribution warehouse, a job that puts him in close proximity to moving loads and elevated racking for most of an eight-hour shift. He first noticed episodes of racing heartbeat eight months ago — sudden onset, no clear trigger, lasting anywhere from a few minutes to over an hour, usually easing on their own or with a Valsalva maneuver he learned from an internet search before ever seeing a doctor about it.
An event monitor eventually captured several episodes, heart rates in the 180s, with a QRS morphology consistently showing right bundle branch block and left axis deviation — a pattern specific enough that it named its own likely diagnosis before any further workup was done. He has no family history of sudden cardiac death, no syncope during his episodes (one near-fainting spell), and a transthoracic echocardiogram showing normal chamber sizes, normal ejection fraction, and no wall motion abnormalities. Nothing in his history or standard imaging argues against a young, otherwise healthy man having idiopathic fascicular ventricular tachycardia — the question the team is weighing is whether standard imaging is thorough enough to rest that diagnosis on, given what's riding on getting it right.
Verapamil's effectiveness in this arrhythmia is thought to work by blocking a calcium-dependent slow-conduction zone within a reentry circuit specific to Purkinje-fascicular tissue, a mechanism distinct from how it's used for supraventricular arrhythmias or hypertension, which is part of why the diagnosis and the drug are so tightly linked in the literature — confirm one and the other follows naturally. The complicating factor is that the Purkinje-related VT that can mimic this exact ECG pattern arises through an overlapping, structurally-dependent version of the same triggered mechanism, meaning the two conditions can look nearly identical on a monitor while calling for genuinely different risk calculations underneath.
One more test before committing to verapamil
His ECG morphology is about as classic as this presentation gets — right bundle branch block, left axis deviation, a QRS that's relatively narrow for ventricular tachycardia — and his echo is clean. I'd start verapamil now. This arrhythmia responds to it reliably, the drug is low-risk in the setting we believe we're looking at, and there's no reason to make him wait for further imaging before getting a treatment that's likely to work.
I'd get a cardiac MRI before committing him to long-term verapamil — not instead of starting treatment now, but running in parallel. There's a specific, published mimic of this exact ECG pattern — Purkinje-related ventricular tachycardia arising from occult structural disease, most often described post-infarction — that a standard echocardiogram isn't sensitive enough to reliably exclude. Verapamil in a patient with real structural VT is a different risk calculation entirely, not just a less effective one.
I'm not disputing the diagnosis is likely correct — I'm saying “likely correct based on morphology and a normal echo” and “confirmed” are different confidence levels, and the difference matters more here than in a case where nothing depended on getting it right.
What tips it for me is what he does for work. He operates a forklift around elevated racking and other people, which means a wrong diagnosis carrying a hidden structural substrate isn't just a clinical loose end — it's an occupational safety question with real stakes beyond his own health. I'd get the MRI, and I don't think starting verapamil now while it's pending costs him anything, given how well this arrhythmia typically responds to it in the classic presentation.
Started on oral verapamil today, with a cardiac MRI ordered the same visit to confirm the absence of occult structural disease before he's committed to long-term therapy.
The idiopathic fascicular VT diagnosis is considered confirmed, and verapamil continues as definitive long-term therapy.
Verapamil is reassessed entirely, and the team returns to the table with a different risk calculation than the one they started with.
The group agreed on starting treatment today and agreed on getting the MRI; what they haven't fully worked out is the specific branch plan if the imaging comes back with something unexpected, which they've acknowledged openly rather than treating the question as already answered.